Researchers reported progress toward direct genetic programming of neutrophils for glioma by developing in vivo CAR-neutrophils. The approach targets a key historical barrier: neutrophils have been difficult to modify genetically despite being abundant in circulation and active in the tumor microenvironment. The report frames the work as enabling new CAR-neutrophil strategies for brain tumors, where matching therapeutic biology to the local immune context is often central to efficacy.